^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PIGF inhibitor

    Related drugs:
    3d
    An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer (clinicaltrials.gov)
    P1, N=8, Completed, Precision Biotech Taiwan Corp.
    New P1 trial
    |
    Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • PB101
    4d
    Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration (clinicaltrials.gov)
    P=N/A, N=54, Recruiting, Saglik Bilimleri Universitesi | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    10d
    The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=38, Completed, Asan Medical Center | Unknown status --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    21d
    SAHLVE: The Sahlgrenska Anti-VEGF Study (clinicaltrials.gov)
    P2, N=402, Active, not recruiting, Vastra Gotaland Region | Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> May 2027 | Trial primary completion date: Sep 2024 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Eylea (aflibercept intravitreal)
    23d
    Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration (clinicaltrials.gov)
    P=N/A, N=54, Not yet recruiting, Saglik Bilimleri Universitesi
    New trial • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    25d
    The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema (clinicaltrials.gov)
    P=N/A, N=2500, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting
    Enrollment closed • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    29d
    ZEB1 and Uveal Melanoma Invasiveness. (PubMed, Int J Mol Sci)
    Effects of siRNA-dependent ZEB1 knockdown on UM cell proliferation and their sensitivity to the VEGF-A inhibitor Eylea (aflibercept) were tested by MTT and in a real-time proliferation assay...In addition, there is probably a ZEB1 feedback loop that is sensitive to a drop in VEGF-A concentration. The data obtained allow us to consider ZEB1 silencing as an auxiliary link for a combined strategy of killing UM cells.
    Journal
    |
    KDR (Kinase insert domain receptor) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
    |
    Eylea (aflibercept intravitreal)
    1m
    DEUTERON: A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=51, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    1m
    A Comparative Study on the Efficacy of Aflibercept biosimilar versus the Aflibercept Intravitreous Injection in the Treatment of Refractory nAMD (ChiCTR2500108770)
    P=N/A, N=80, Not yet recruiting, Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical Univer
    New trial
    |
    Eylea (aflibercept intravitreal)
    1m
    VGFTe-OD-2457: A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US) (clinicaltrials.gov)
    P=N/A, N=550000, Completed, Regeneron Pharmaceuticals | Recruiting --> Completed
    Trial completion • HEOR • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    1m
    Leveraging the htsFLT01/MiRGD Complex to Enhance Apoptosis and Suppress Angiogenesis in MCF7 Breast Cancer Cells. (PubMed, Iran J Med Sci)
    This study evaluated the effect of this complex on apoptosis induction in MCF7 cells via the extrinsic apoptotic pathway, revealing increased expression of FADD, CASP8, and p53 genes. These findings highlight a synergistic relationship between anti-angiogenic and pro-apoptotic mechanisms, offering promising avenues for future breast cancer therapies.
    Journal
    |
    FADD (Fas associated via death domain) • CASP8 (Caspase 8)
    |
    GZ402663
    2ms
    FIREFLEYE next: Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 (clinicaltrials.gov)
    P3, N=100, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)